By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Ergotamine

Ergotamine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|666 words

What is Ergotamine?

Ergotamine is an ergot alkaloid medication that belongs to the class of drugs known as antimigraine agents or ergot derivatives. It is primarily used to treat acute migraine headaches and cluster headaches by constricting blood vessels in the brain. This medication has been used for decades as an effective treatment for severe headache disorders when other medications have failed to provide relief.

Uses

  • Acute migraine treatment: Ergotamine is used to abort migraine headaches that are already in progress, particularly when accompanied by nausea and vomiting
  • Cluster headache management: Helps terminate acute cluster headache episodes, which are severe, recurring headaches that occur in cyclical patterns
  • Vascular headaches: Treats other types of vascular headaches that involve dilation of blood vessels in the brain
  • Migraine prevention (limited use): Sometimes prescribed for prevention of frequent migraines when other preventive medications are not suitable, though this is less common
  • Post-dural puncture headaches: Occasionally used to treat severe headaches that occur after spinal procedures

How it works

Ergotamine works by binding to serotonin receptors in blood vessels, particularly in the brain, causing these vessels to constrict or narrow. This vasoconstriction helps counteract the blood vessel dilation that contributes to migraine and cluster headache pain. The medication also affects dopamine and norepinephrine receptors, which may contribute to its effectiveness in treating severe headaches.

Side effects

Common side effects:

  • Nausea and vomiting
  • Dizziness and weakness
  • Muscle pain and stiffness
  • Cold hands and feet
  • Abdominal cramping
  • Tingling or numbness in fingers and toes
  • Drowsiness
  • Diarrhea

Serious side effects requiring immediate medical attention:

Submit Your Paper
GMJ_Submit_Banner
  • Severe chest pain or heart rhythm changes
  • Signs of reduced blood flow to extremities (severe coldness, pain, or color changes in hands or feet)
  • Severe abdominal pain or persistent vomiting
  • Signs of ergotism (severe vasoconstriction causing tissue damage)
  • Severe leg cramps or pain while walking

Warnings and precautions

  • Cardiovascular conditions: Should not be used by patients with coronary artery disease, peripheral vascular disease, or uncontrolled high blood pressure due to risk of dangerous vasoconstriction
  • Pregnancy and breastfeeding: Contraindicated in pregnancy as it can cause uterine contractions and potential harm to the fetus; also not recommended during breastfeeding
  • Liver and kidney disease: Use with extreme caution in patients with liver or kidney impairment as the drug may accumulate to toxic levels
  • Overuse risk: Can cause medication overuse headaches and physical dependence if used too frequently; should not be used more than twice per week
  • Age restrictions: Generally not recommended for elderly patients due to increased risk of vascular complications

Interactions

  • CYP3A4 inhibitors (ketoconazole, erythromycin): Can increase ergotamine levels to dangerous concentrations, potentially causing ergot toxicity
  • Triptans (sumatriptan, rizatriptan): Should not be used within 24 hours of each other due to additive vasoconstriction effects
  • Beta-blockers (propranolol, metoprolol): May enhance vasoconstriction and increase risk of peripheral vascular problems
  • Nicotine: Smoking or nicotine products can worsen vasoconstriction and increase risk of serious circulation problems
  • HIV protease inhibitors (ritonavir, indinavir): Can significantly increase ergotamine levels and risk of toxicity
  • SSRIs and SNRIs: May increase risk of serotonin-related side effects when used together
  • Caffeine: Often combined with ergotamine therapeutically but can also enhance absorption and potentially increase side effects
  • Vasoconstrictors: Other medications that constrict blood vessels should be avoided to prevent dangerous additive effects

Check interactions with the GMJ Interaction Checker

Dosage

For acute migraine treatment, the typical adult dose is 1-2 mg at the onset of headache symptoms, which may be repeated every 30 minutes if needed. The maximum recommended dose is usually 6 mg per attack and no more than 10 mg per week. For cluster headaches, dosing may be similar but should be carefully monitored. Ergotamine is available in various forms including tablets, sublingual tablets, and suppositories. All dosing should be individualized and determined by a healthcare provider based on the patient’s specific condition, response to treatment, and risk factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Ergotamine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/ergotamine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy

New genetic testing could spare 6,600 UK breast cancer patients annually from…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Kava

By
Prof. Giorgi Pkhakadze
02/06/2026

Tiotropium

By
Prof. Giorgi Pkhakadze
02/06/2026

Trimethoprim/Sulfamethoxazole

By
Prof. Giorgi Pkhakadze
02/06/2026

St John’s Wort

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up